+1 (888) 794-0077

Peptide Testing Services

Peptides are a unique class of pharmaceutical compounds that have gained considerable interest due to their potential across a spectrum of diseases, including metabolic disorders, cardiovascular issues, cancer, and infectious diseases. Our comprehensive peptide testing services cover the entire scope of drug development, from discovery to IND application to NDA submission, allowing you to advance novel therapies further, faster.

Peptide Testing Services by WuXi AppTec Lab Testing Division

IND-Enabling Packages

In Vitro Studies

In Vivo Studies

Why Peptides Need Specialized Development Support

 

Peptides are highly specific and biologically active—but their success depends on solving critical development challenges:

  • High molecular weight in comparison to traditional small molecules and polarity limit permeability
  • Rapid enzymatic degradation reduces stability
  • Complex bioanalytical properties challenge assay design
  • Risk of immunogenicity (anti-drug antibodies)
  • Specialized toxicology assessments required

At WuXi AppTec, our global network of and experienced teams help you overcome these challenges with seamless, efficient testing solutions.

Overcoming Peptide Development Challenges

Peptides present a number of challenges during preclinical development that can easily turn into costly delays and additional testing—especially if you don’t have an experienced guide. Here’s how we can help.

Stage: In Vitro

 

Peptide-Specific Challenge

  • Rapid enzymatic degradation
  • Poor permeability due to high polarity
  • High protein binding and non-specific adsorption

WuXi AppTec’s solution

  • Advanced stability testing in plasma, liver/kidney S9 fractions, hepatocytes, and simulated gastric/intestinal fluids
  • Permeability assessment using Caco-2, MDCK, and EPSA measurements for passive and endocytotic uptake
  • Radiolabeling (e.g., 14C) to enable definitive metabolism and soft-spot studies
  • Custom assay development to characterize metabolic pathways and degradation profiles

Stage: In Vivo

 

Peptide-Specific Challenge

  • Low systemic exposure after administration
  • Complex tissue distribution, especially for oral and injectable routes
  • Barriers to achieving therapeutic concentrations at target sites

WuXi AppTec’s solution

  • Tailored IV, SC, and oral PK study design in relevant species
  • Radiolabeling strategies for tissue distribution, excretion, and QWBA studies
  • Formulation support for bioavailability enhancement (e.g., permeability enhancers, cyclic peptide design)

Stage: Bioanalysis

 

Peptide-Specific Challenge

  • High structural diversity impacting assay sensitivity and specificity
  • Non-specific binding in plasma due to hydrophobic modifications or formulation excipients
  • Matrix effects complicating quantification
  • Need for robust ADA (anti-drug antibody) detection and immunogenicity monitoring

WuXi AppTec’s solution

  • Full LC-MS/MS and LBA platforms optimized for peptides, including hybrid LBALCMS (immunocapture + MS readout) for sensitivity & selectivity
  • Advanced sample preparation to minimize non-specific binding (e.g., NSB blockers, low-binding tubes)
  • Method development to overcome matrix effects, ensuring assay robustness and reproducibility

Stage: Early Toxicology

 

Peptide-Specific Challenge

  • Selecting relevant species given differences in peptide metabolism and immunogenicity
  • Assessing local toxicity for SC/IV/oral administration
  • Evaluating dose ranges in exploratory studies

WuXi AppTec’s solution

  • Species selection guided by PK and immunogenicity profiles to ensure relevance
  • Early safety pharmacology studies covering CNS, cardiovascular, and respiratory systems
  • Immunogenicity risk assessments and ADA monitoring in non-GLP settings

Stage: GLP Toxicology

 

Peptide-Specific Challenge

  • Meeting regulatory expectations for repeat-dose toxicity and immunogenicity assessments
  • Managing potential off-target effects and local irritation

WuXi AppTec’s solution

  • GLP-compliant repeat-dose studies in rodents and non-rodents with immunogenicity monitoring
  • Robust species selection strategy in line with ICH guidelines (M3, S6)
  • Genetic toxicology studies tailored to peptide modifications and non-natural amino acids
  • Comprehensive reproductive, carcinogenicity, and local toxicity studies as required for IND submission

Stage: IND Submission

 

Peptide-Specific Challenge

  • Ensuring consistency and integration across DMPK, bioanalysis, and toxicology data
  • Preparing clear, complete packages for regulatory submission
  • Addressing evolving regulatory expectations for peptide therapeutics

WuXi AppTec’s solution

  • Integrated project teams coordinating DMPK, bioanalysis, and toxicology
  • Regulatory strategy consulting to address immunogenicity, ADA assessments, and safety study design
  • Flexible, scalable capabilities to support submissions worldwide

End-to-End Preclinical Services

WuXi AppTec offers a comprehensive testing platform for peptides from the early screening stage to IND submission and beyond. With an experienced peptide research team and cutting-edge instruments and equipment, WuXi AppTec is equipped with comprehensive peptide study and analysis capabilities to ensure the delivery of high-quality in vivo and in vitro data.

Custom Study Strategies

Our team specializes in designing customized study strategies for peptide molecules, which are larger and more structurally complex than small molecules. By proactively identifying potential safety concerns early in the process, we empower drug developers to make informed decisions regarding the advancement of peptide drugs into clinical trials.

Global Partner & Network

WuXi AppTec is a true global provider in preclinical small and large molecule solutions, with state-of-the-art facilities and experts across US, Europe and China. We have decades of experience operating within diverse regulatory environments and delivering tailored testing solutions that advance ADCs from preclinical through IND, NDA and beyond.

Comprehensive Preclinical
Testing for Peptides

Peptides are composed of a series of well-ordered amino acids with molecular weights between 500 and 5,000 Da – a unique structure that requires specialized preclinical testing techniques. With capabilities in DMPK/ADME, bioanalysis, safety assessment, pharmacology, and CMC, WuXi AppTec can support every aspect of peptide development – all conveniently under one roof.

DMPK

Access a global network of testing facilities for peptide DMPK research, focusing on peptide stability, permeation, delivery carrier, and tissue distribution studies.

Bioanalysis

We develop and validate robust analytical methods tailored to the unique characteristics of peptides, with high specificity and sensitivity.

Toxicology

Our comprehensive safety assessment services are tailored to peptide drug characteristics. We consider immunogenicity, off-target effects, metabolic stability, routes of administration, dose-dependency, and more.

New Insights for New Modalities

BROCHURE

Preclinical Drug Development Testing for Peptide-Drug Conjugate Brochure

WEBINAR

Peptide Therapeutics: Navigating Development with DMPK & Toxicology

BROCHURE

Laboratory Testing Division Bioanalytical Services: BAS GLP-1 Brochure

BLOG

Bioanalytical Strategies for Peptide-Drug Conjugates (PDCs): Optimized Approaches for the Pharmaceutical Industry

Frequently Asked Questions

What are peptides?

Therapeutic peptides are a unique class of pharmaceutical compounds composed of a series of well-ordered amino acids, usually with molecular weights of 500 – 5,000 Da. They act as agonists or antagonists of particular receptors, enzymes, or proteins, thereby modulating physiological processes. 

What are the biggest therapeutic opportunities related to peptides?

Peptide drugs have gained considerable interest due to their potential across a spectrum of diseases, including metabolic disorders, cardiovascular issues, cancer, and infectious diseases. The recent blockbuster drug glucagon-like peptide-1 (GLP-1) hormone stands as a great example of the efficacy and promise offered by peptide therapeutics in clinical practice.

Why is preclinical testing important for peptides?

Preclinical testing is crucial for peptides to evaluate their safety, efficacy, and pharmacokinetics before they enter clinical trials. It helps identify any potential toxic effects, optimal dosing regimens, and therapeutic potential, ensuring that only promising candidates proceed to human trials.

How is preclinical testing for peptides different from other types of molecules?

Preclinical DMPK research on peptides mainly focuses on stability, permeation, delivery carrier, and tissue distribution studies. Bioanalytical method development focuses on detecting and quantifying the peptide in biological samples with high specificity and sensitivity.

What are some challenges of peptide development and testing?

Peptide development and testing face numerous challenges, including the need for highly sensitive and specific analytical methods to detect and quantify these larger, structurally complex molecules in biological matrices. Peptides are physiologically active, requiring small dosages and resulting in low in vivo drug concentrations amid many endogenous interfering substances. Mass spectrometry is complicated by the generation of multiple charged ions and dispersed ions of different valence states. Additionally, peptides exhibit issues such as non-specific adsorption, low stability, and high protein binding ratios, which complicate sample processing and detection. Their high polarity and poor permeability hinder their ability to cross bio-membrane barriers, reducing oral bioavailability. Peptides also suffer from poor metabolic stability, multiple metabolic pathways, and short half-lives.

What types of preclinical studies are essential for peptides?

Preclinical studies are crucial for evaluating the properties and behavior of peptides to ensure their safety and efficacy before clinical trials. These studies encompass several stages, each focusing on different aspects: 

  • Early screening stage: Mainly investigating the in vitro properties of peptide molecules (including plasma stability, metabolic stability, permeation, and protein binding) and guiding molecular structure optimization. The interactions and enzyme phenotyping of peptides with low molecular weight are evaluated as well.
  • PCC stage: This stage focuses on the metabolic differences of species and the in vivo PK study of peptides. It aims to select the appropriate species for relevant research by considering both pharmacodynamics and toxicology. The study of various delivery carriers makes it possible to achieve the desired in vivo exposure characteristics.
  • IND stage: In this stage, single dose escalation and repeated administration PK in animals will be studied. The excretion pathway (mass balance), tissue distribution, and in vivo metabolites identification also need be evaluated.

What safety assessments are critical in the preclinical testing of peptides?

Immunogenicity tests are particularly important for peptides due to the potential for peptides to elicit immune responses. Acute and chronic toxicity studies are conducted to determine the toxic effects over different exposure periods. Genotoxicity studies evaluate any risk of genetic damage, and safety pharmacology studies monitor vital functions such as cardiovascular, respiratory, and central nervous systems.

What considerations are important for DMPK studies on peptides?

For Drug Metabolism and Pharmacokinetics (DMPK) studies on peptides, it is important to consider the peptide’s stability, bioavailability, and routes of administration. The potential for enzymatic degradation, the impact of formulation on absorption, and the peptide’s distribution and elimination pathways are also critical factors.

What regulatory guidelines must be followed for preclinical testing of peptides?

Preclinical testing of peptides must adhere to regulatory guidelines such as those from the FDA, EMA, and ICH, which include Good Laboratory Practice (GLP) standards. Specific guidelines for biologics, including peptides, cover aspects such as immunogenicity (ICH S6(R1)), toxicology studies (ICH M3(R2)), and the evaluation of safety pharmacology (ICH S7A).

What are the potential pharmacological concerns of peptides?

Pharmacological concerns specific to peptides include their rapid degradation by proteases in the body, leading to poor bioavailability and short half-lives. Peptides can also be immunogenic, potentially triggering unwanted immune responses. Their specificity to target receptors may cause off-target effects, and they often require advanced delivery systems to achieve therapeutic levels.

What efficacy tests are conducted for peptides in preclinical studies?

Efficacy tests for peptides involve in vitro assays to assess their interaction with target receptors or enzymes and to measure biological activity. In vivo studies use animal models of the target disease to evaluate therapeutic outcomes, such as reduction in disease biomarkers, improvement in clinical symptoms, and overall survival rates, providing a comprehensive assessment of the peptide’s therapeutic potential.

What analytical methods are used in peptide preclinical testing?

Peptides require the development and validation of robust analytical methods tailored to their unique characteristics. This may involve optimizing sample preparation techniques, selecting appropriate analytical platforms such as liquid chromatography-mass spectrometry (LC-MS) or enzyme-linked immunosorbent assay (ELISA), and implementing stringent quality control measures to ensure the accuracy and reliability of peptide quantification in preclinical studies.

Let’s Talk About Your Peptide Program

Have questions? Need specific assays? Talk to an expert today about your peptide needs.